Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
ABIO's Cash to Debt is ranked higher than
95% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. ABIO: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ABIO' s Cash to Debt Range Over the Past 10 Years
Min: 0.36  Med: 15.93 Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: 9.90
M-Score: -3.60
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -38.20
ABIO's ROE (%) is ranked lower than
55% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -31.46 vs. ABIO: -38.20 )
Ranked among companies with meaningful ROE (%) only.
ABIO' s ROE (%) Range Over the Past 10 Years
Min: -206.23  Med: -96.98 Max: -17.89
Current: -38.2
-206.23
-17.89
ROA (%) -36.57
ABIO's ROA (%) is ranked lower than
59% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -26.29 vs. ABIO: -36.57 )
Ranked among companies with meaningful ROA (%) only.
ABIO' s ROA (%) Range Over the Past 10 Years
Min: -96.07  Med: -70.79 Max: -8.06
Current: -36.57
-96.07
-8.06
ROC (Joel Greenblatt) (%) -35095.09
ABIO's ROC (Joel Greenblatt) (%) is ranked lower than
95% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. ABIO: -35095.09 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ABIO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -35753.13  Med: -1226.76 Max: -180.91
Current: -35095.09
-35753.13
-180.91
EBITDA Growth (3Y)(%) -48.70
ABIO's EBITDA Growth (3Y)(%) is ranked lower than
92% of the 497 Companies
in the Global Biotechnology industry.

( Industry Median: -0.30 vs. ABIO: -48.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ABIO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -73.4  Med: -38.30 Max: 19.5
Current: -48.7
-73.4
19.5
EPS Growth (3Y)(%) -48.90
ABIO's EPS Growth (3Y)(%) is ranked lower than
91% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. ABIO: -48.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ABIO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -72.5  Med: -38.30 Max: 24.5
Current: -48.9
-72.5
24.5
» ABIO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ABIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.96
ABIO's P/B is ranked higher than
93% of the 843 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. ABIO: 0.96 )
Ranked among companies with meaningful P/B only.
ABIO' s P/B Range Over the Past 10 Years
Min: 0.01  Med: 0.17 Max: 14.11
Current: 0.96
0.01
14.11
EV-to-EBIT 0.20
ABIO's EV-to-EBIT is ranked higher than
93% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.70 vs. ABIO: 0.20 )
Ranked among companies with meaningful EV-to-EBIT only.
ABIO' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.5  Med: 1.20 Max: 2.2
Current: 0.2
-10.5
2.2
EV-to-EBITDA 0.20
ABIO's EV-to-EBITDA is ranked higher than
93% of the 275 Companies
in the Global Biotechnology industry.

( Industry Median: 20.64 vs. ABIO: 0.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.9  Med: 1.20 Max: 2.5
Current: 0.2
-10.9
2.5
Current Ratio 25.88
ABIO's Current Ratio is ranked higher than
94% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. ABIO: 25.88 )
Ranked among companies with meaningful Current Ratio only.
ABIO' s Current Ratio Range Over the Past 10 Years
Min: 0.22  Med: 5.17 Max: 25.88
Current: 25.88
0.22
25.88
Quick Ratio 25.88
ABIO's Quick Ratio is ranked higher than
94% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. ABIO: 25.88 )
Ranked among companies with meaningful Quick Ratio only.
ABIO' s Quick Ratio Range Over the Past 10 Years
Min: 0.22  Med: 5.17 Max: 25.88
Current: 25.88
0.22
25.88

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.98
ABIO's Price/Net Cash is ranked higher than
97% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 5.74 vs. ABIO: 0.98 )
Ranked among companies with meaningful Price/Net Cash only.
ABIO' s Price/Net Cash Range Over the Past 10 Years
Min: 1.13  Med: 4.61 Max: 29.54
Current: 0.98
1.13
29.54
Price/Net Current Asset Value 0.97
ABIO's Price/Net Current Asset Value is ranked higher than
97% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 5.40 vs. ABIO: 0.97 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ABIO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.13  Med: 3.89 Max: 55.72
Current: 0.97
1.13
55.72
Price/Tangible Book 0.95
ABIO's Price/Tangible Book is ranked higher than
95% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. ABIO: 0.95 )
Ranked among companies with meaningful Price/Tangible Book only.
ABIO' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.11  Med: 3.33 Max: 49.81
Current: 0.95
1.11
49.81
Earnings Yield (Greenblatt) (%) 474.41
ABIO's Earnings Yield (Greenblatt) (%) is ranked higher than
98% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. ABIO: 474.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ABIO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 45.7  Med: 80.15 Max: 9231.6
Current: 474.41
45.7
9231.6

More Statistics

Revenue(Mil) $0
EPS $ -2.27
Beta0.46
Short Percentage of Float1.92%
52-Week Range $3.05 - 10.85
Shares Outstanding(Mil)9.06

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 20 53
EPS($) -0.20 0.10 0.59
EPS without NRI($) -0.20 0.10 0.59

Business Description

Industry: Biotechnology » Biotechnology
Compare:XKRX:066430, TSX:IMV, XPAR:ALQGC, WAR:PHR, TSXV:BTI, ASX:ANR » details
Traded in other countries:HQ1N.Germany,
ARCA biopharma, Inc., was originally incorporated as Hyseq, Inc. in Illinois in 1992 and reincorporated in Nevada in 1993. On January 31, 2003, Nuvelo merged with Variagenics, Inc., a publicly traded Delaware corporation based in Massachusetts, and, in connection with the merger, changed its name to Nuvelo, Inc. On March 25, 2004, it was reincorporated from Nevada to Delaware. On January 27, 2009, in connection with the Merger with ARCA Colorado described above, Nuvelo changed its name to ARCA biopharma, Inc. Its main offices are located in Broomfield, Colorado. It is a biopharmaceutical company whose focus is developing genetically-targeted therapies for cardiovascular diseases. Its product candidate, Gencaro TM (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator, is being developed for the treatment of atrial fibrillation (AF) in patients with heart failure (HF). The company has been granted patents in the U.S., Europe, and other jurisdictions for methods of treating AF and HF patients with Gencaro based on genetic testing. The company outsources all manufacturing and analytical testing of the Gencaro API and drug product. The company is contracted with Groupe Novasep to complete the drug substance registration batches required for the Gencaro NDA. These batches were successful, and the resulting drug substance was used to supply the drug product registration campaign. For drug product production, the company has contracted with Patheon, Inc. to manufacture the Gencaro tablets. Gencaro is produced in a tablet form, utilizing standard solid oral dosage processing techniques. The Company faces competition from pharmaceutical companies and biotechnology companies that are researching and selling products designed to treat cardiovascular conditions. Governmental authorities in the U.S. at the federal, state, and local levels and foreign countries regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, marketing, distribution, sampling, and import and export of pharmaceutical and medical device products.
» More Articles for ABIO

Headlines

Articles On GuruFocus.com
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Nov 15 2010 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Aug 10 2010 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) May 10 2010 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Nov 16 2009 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Aug 10 2009 
ARCA biopharma Inc. Reports Operating Results (10-Q) May 15 2009 
ARCA biopharma Inc. Reports Operating Results (10-Q) Feb 07 2009 

More From Other Websites
ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 18 2016
ARCA biopharma Announces 75th Patient Enrolled in Genetic-AF Phase 2B/3 Clinical Trial Apr 18 2016
ARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial Apr 18 2016
ARCA BIOPHARMA, INC. Financials Mar 23 2016
ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 17 2016
ARCA biopharma Announces Fiscal Year 2015 Financial Results and Provides Business Update Mar 17 2016
ARCA BIOPHARMA, INC. Files SEC form 10-K, Annual Report Mar 17 2016
Bearish case for Valeant Mar 17 2016
ARCA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Mar 07 2016
ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 16 2016
ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 12 2016
GENETIC-AF Clinical Trial for Prevention of Atrial Fibrillation Enrolls 50th Patient Jan 12 2016
Applying Lessons from KBIO Dec 08 2015
2 Micro-Cap Opportunities in Atrial Fibrillation Nov 30 2015
Biotechs Under 20 Dollars Poised to Breakout Nov 23 2015
ARCA biopharma to Present at the 27th Annual Piper Jaffray Healthcare Conference Nov 19 2015
2 Important Takeaways from ARCA Biopharma's Q3 Results Nov 18 2015
ARCA biopharma Announces Third Quarter 2015 Financial Results and Provides Business Update Nov 12 2015
ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 12 2015
ARCA biopharma Announces Third Quarter 2015 Financial Results and Provides Business Update Nov 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK